X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (62) 62
index medicus (60) 60
gastroenterology & hepatology (57) 57
male (44) 44
female (43) 43
middle aged (37) 37
adult (26) 26
aged (21) 21
hepatitis c (19) 19
spain (17) 17
treatment outcome (17) 17
cirrhosis (15) 15
medicine, general & internal (15) 15
hepatitis c, chronic - drug therapy (14) 14
antiviral agents - therapeutic use (13) 13
risk factors (12) 12
gastroenterology and hepatology (11) 11
retrospective studies (11) 11
animals (10) 10
hepatitis c, chronic - virology (10) 10
aged, 80 and over (9) 9
hepacivirus - genetics (9) 9
liver (9) 9
virus-infection (9) 9
biomarkers - blood (8) 8
drug therapy, combination (8) 8
fibrosis (8) 8
genotype (8) 8
hepatocellular-carcinoma (8) 8
liver cirrhosis - physiopathology (8) 8
liver diseases (8) 8
patients (8) 8
risk (8) 8
analysis (7) 7
antiviral agents - administration & dosage (7) 7
chronic hepatitis c (7) 7
disease (7) 7
disease progression (7) 7
hepatitis (7) 7
infection (7) 7
interferon (7) 7
oncology (7) 7
pharmacology & pharmacy (7) 7
prevalence (7) 7
ribavirin (7) 7
safety (7) 7
sustained virological response (7) 7
viral load (7) 7
association (6) 6
cohort studies (6) 6
colonoscopy (6) 6
digestive system diseases (6) 6
hcv (6) 6
predictive value of tests (6) 6
ribavirin - administration & dosage (6) 6
sofosbuvir (6) 6
cancer (5) 5
care and treatment (5) 5
diagnosis (5) 5
dna, viral - blood (5) 5
epidemiology (5) 5
hepatitis b virus - genetics (5) 5
hepatitis b virus - immunology (5) 5
hepatitis c antibodies - blood (5) 5
hepatitis c, chronic - complications (5) 5
incidence (5) 5
infectious diseases (5) 5
inflammation (5) 5
interferon-alpha - therapeutic use (5) 5
liver - virology (5) 5
liver cirrhosis - blood (5) 5
liver cirrhosis - complications (5) 5
liver cirrhosis - virology (5) 5
mice (5) 5
nafld (5) 5
polyethylene glycols - therapeutic use (5) 5
ribavirin - therapeutic use (5) 5
spain - epidemiology (5) 5
steatosis (5) 5
time factors (5) 5
treatment-experienced patients (5) 5
virus activation (5) 5
young adult (5) 5
adolescent (4) 4
antiviral agents - adverse effects (4) 4
ascites (4) 4
biological products (4) 4
biopsy (4) 4
cell death (4) 4
chronic infection (4) 4
colorectal cancer (4) 4
diabetes mellitus (4) 4
double-blind method (4) 4
genotype 1 infection (4) 4
glomerular filtration rate (4) 4
hbv infection (4) 4
hepatitis b surface antigens - blood (4) 4
hepatitis b virus (4) 4
hepatitis b virus - growth & development (4) 4
hepatitis b virus - pathogenicity (4) 4
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 09/2017, Volume 377, Issue 12, pp. 1119 - 1131
Patients with myocardial infarction and a high-sensitivity CRP level of 2 mg or more per liter were assigned to one of three canakinumab doses or placebo. The... 
no | C-REACTIVE PROTEIN | MEDICINE, GENERAL & INTERNAL | HEART-DISEASE | MYOCARDIAL-INFARCTION | STATIN THERAPY | CLONAL HEMATOPOIESIS | INFLAMMATION | CARDIOVASCULAR-DISEASE | INTERLEUKIN-1-BETA INHIBITION | RISK | CORONARY-ARTERY-DISEASE | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Male | Secondary Prevention | Infection - etiology | Incidence | Dose-Response Relationship, Drug | Anti-Inflammatory Agents - adverse effects | C-Reactive Protein - metabolism | Lipids - blood | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Anti-Inflammatory Agents - administration & dosage | Female | Neutropenia - chemically induced | Interleukin-1beta - antagonists & inhibitors | Stroke - prevention & control | Atherosclerosis - drug therapy | Double-Blind Method | Interleukin-1beta - immunology | Atherosclerosis - blood | Myocardial Infarction - drug therapy | Antibodies, Monoclonal - administration & dosage | Aged | Myocardial Infarction - prevention & control | Myocardial infarction | Cerebral infarction | Stroke | Heart attacks | C-reactive protein | Cytokines | Clinical trials | Cardiovascular disease | Innate immunity | Inflammation | Angina | Angina pectoris | Thrombosis | Cholesterol | Disease prevention | Proteins | Arteriosclerosis | Atherosclerosis | Cardiovascular diseases | Health risk assessment | Drug therapy | Drug dosages | Klinisk medicin | Clinical Medicine
Journal Article
PLoS ONE, ISSN 1932-6203, 09/2012, Volume 7, Issue 9, p. e45285
A role for the NADPH oxidases NOX1 and NOX2 in liver fibrosis has been proposed, but the implication of NOX4 is poorly understood yet. The aim of this work was... 
GROWTH-FACTOR-BETA | OXIDATIVE STRESS | TGF-BETA | INDUCED APOPTOSIS | ADENINE-DINUCLEOTIDE PHOSPHATE | MULTIDISCIPLINARY SCIENCES | FIBROGENESIS | DIFFERENTIATION | MESENCHYMAL TRANSITION | UP-REGULATION | Liver - virology | Hepatitis C, Chronic - pathology | Liver - enzymology | Gene Expression - drug effects | Apoptosis - drug effects | ATP Binding Cassette Transporter, Sub-Family B - deficiency | Carbon Tetrachloride | Humans | NADPH Oxidases - metabolism | Hepatitis C, Chronic - virology | Myofibroblasts - enzymology | Liver Cirrhosis - enzymology | Liver Cirrhosis - chemically induced | Liver - drug effects | Cell Transdifferentiation - drug effects | Hepatitis C, Chronic - enzymology | STAT3 Transcription Factor - deficiency | NADPH Oxidases - genetics | Hepacivirus - physiology | Hepatic Stellate Cells - virology | Myofibroblasts - virology | Hepatocytes - drug effects | STAT3 Transcription Factor - genetics | Hepatic Stellate Cells - drug effects | Cyclin-Dependent Kinase Inhibitor p16 - deficiency | Hepatic Stellate Cells - enzymology | Cyclin-Dependent Kinase Inhibitor p16 - genetics | NADPH Oxidase 4 | Myofibroblasts - drug effects | Mice, Knockout | Transforming Growth Factor beta - pharmacology | Animals | Liver Cirrhosis - virology | Signal Transduction - drug effects | Biopsy | Hepatocytes - virology | Liver Cirrhosis - pathology | Mice | ATP Binding Cassette Transporter, Sub-Family B - genetics | Hepatocytes - enzymology | Oxidases | Care and treatment | Liver diseases | Research | Gene expression | Liver cells | Animal models | Biomedical research | Mesenchyme | Liver | Carbon tetrachloride | Viruses | Activation | Metastasis | Experiments | NAD(P)H oxidase | Hepatitis | Genotype & phenotype | Cell activation | NOX4 protein | Rodents | Hepatology | Gastroenterology | CYBB protein | Fibroblasts | Growth factors | Medical research | Stellate cells | Patients | Pulmonary fibrosis | Hepatocytes | Cell death | Fibrosis | Hepatitis C virus | Hepatitis C | Cancer | Apoptosis | Bile | Malalties del fetge | Cèl·lules hepàtiques
Journal Article
Journal Article
Journal Article
Alimentary Pharmacology & Therapeutics, ISSN 0269-2813, 12/2018, Volume 48, Issue 11-12, pp. 1260 - 1270
Journal Article